scientific meeting - overview - Hertie-Institut für klinische Hirnforschung

The Local Organization Commmittee
Mathias Jucker, Jacqueline Mervaillie, Yves Christen, Konrad Beyreuther, Christian Haass, Konrad
Maurer, Roger Nitsch, Gerhard Buchkremer
The Scientific Advisory Board
Karen Ashe, Konrad Beyreuther, Heiko Braak, Jean-Pierre Brion, Yves Christen, Martin Citron, Carl
Cotman, Mony De Leon, Bart De Strooper, Monica Di Luca, Karen Duff, Falk Fahrenholz, Blas
Frangione, Dora Games, Sam Gandy, Michel Goedert, Paul Greengard, John Growdon, Christian
Haass, John Hardy, Jean-Jacques Hauw, David Holtzman, Michael Hutton, Bradley Hyman, Yasuo
Ihara, Khalid Iqbal, Takeshi Iwatsubo, Mathias Jucker, Zaven Khachaturian, June Kinoshita, Eddie
Koo, Frank LaFerla, Peter Lansbury, Lars Lannfelt, Virginia Lee, Eva Mandelkow, Eckard
Mandelkow, Eliezer Masliah, Colin Masters, Mark Mattson, Konrad Maurer, Patrick McGeer, Roger
Nitsch, Margaret Pericak-Vance, George Perry, Don Price, Allen Roses, Gerard Schellenberg, Dale
Schenk, Dennis Selkoe, Sam Sisodia, Peter St George-Hyslop, Gabrielle Strobel, Rudy Tanzi, Robert
Terry, Leon Thal, John Trojanowski, Christine Van Broeckhoven, Bengt Winblad, Michael Wolfe,
Bruce Yankner, Steve Younkin

The Idea
On November 3, 1906 Alois Alzheimer traveled to the university city of Tübingen, Germany,
to present an unusual case of dementia. Auguste D. would become known as the first
documented case of Alzheimer’s disease – a disorder of the brain's nerve cells that impairs
memory, cognition, and behavior. Alzheimer’s disease is widely known today as the most
common form of dementia, which currently affects about 20 million people worldwide. Alois
Alzheimer described the pathological characteristics of the disease in the auditorium of the
Institute of Psychiatry at the University of Tübingen, the same location where we will mark
the 100-year anniversary of Alzheimer’s research.
The objective of this meeting is to serve as a powerful retrospective as well as a forwardreaching
gathering of experts, and to provide an opportunity to promote awareness and
funding of Alzheimer´s disease and brain aging research into the next century. In Germany
and most other industrialized societies the number of people over 65 years of age is projected
to increase dramatically – making research and political awareness for the expected social and
economical burden more essential than ever before.
The historic event will begin in the evening of November 2 with an opening session for the
public. There, a historian, a molecular biologist, a theologian, and an author will reflect on
aging and Alzheimer’s disease. The scientific meeting will start on November 3 with a
retrospective featuring «pioneers» who contributed to Alzheimer’s disease research over the
last 100 years. On November 4, leading scientists will present «current concepts» in
Alzheimer´s disease research in the morning and will discuss the most important «challenges»
for the new century in the afternoon.
The organization committee never felt that they should select the speakers for this centenary

meeting. Thus, a Scientific Advisory Board of 62 scientists was appointed and its members
were invited to vote for potential speakers. Speakers were then selected strictly according to
the votes. Even with these procedures we cannot rule out that some people have been left out
that would have deserved to be invited to speak in Tübingen but it was surely not the
intention of this centenary meeting to exclude anybody.
Due to space limitations in the historic Institute of Psychiatry, the meeting had to be limited to
181 people. We were aware of this limitation and now provide a live video stream as well as a
DVD of the scientific meeting. The idea to move the meeting to another location in Tübingen
did not find the necessary approval since we would have lost the historical link to Alois
Alzheimer´s presentation 100 years ago.
We are extremely happy that none of our requests to speakers for Alzheimer: 100 Years and
Beyond in Tübingen was denied. We hope that the meeting and your stay in Tübingen will be
pleasant and that in some way the spirit of medical research a century ago will reach you. Not
only will the meeting take place at the original lecture hall, but the conference dinner will also
be held at the same restaurant where the congregation had dinner on Nov 3, 1906. We can be
sure, however, that the response of the audience and media will be greater than one hundred
years ago when no questions and virtually no media coverage followed Alzheimer´s milestone
presentation.
Maybe the meeting will make history as the first centenary meeting of Alzheimer’s disease. It
was fun organizing this event; nevertheless, we decided to pass the organization of the second
centenary meeting in 2106 on to somebody else. Saying this, we all hope that there will be no
need for such a second meeting given the enormous progress in the field, and the prospect of
having a preventive treatment in the coming years.
Mathias Jucker
Konrad Beyreuther
Gerhard Buchkremer
Yves Christen
Christian Haass
Konrad Maurer
Jacqueline Mervaillie
Roger Nitsch

Thursday, November 2, 2006
14.00-17.00 Registration at the Clinic of Psychiatry
15.30-17.30 City Tour (please see Additional Program)
18.00 Public Session in German: Altern und Alzheimer
21.00 Die Akte Auguste D. – Theater (in German)
Friday, November 3, 2006
8.50 – 17.20 Scientific Meeting
Session 1: The Pioneers & The Beginning
21.00 Die Akte Auguste D. - Theater
(in English and reserved for the symposium participants)
Saturday, November 4, 2006
9.00 – 16.30 Scientific Meeting
Session 2: Current Concepts
Session 3: Challenges for the Future
17.00 Press Conference
20.00 Conference Dinner
Sunday, November 5, 2006
9.00 Visit to Marktbreit, the birthplace of Alois Alzheimer

SCIENTIFIC MEETING - OVERVIEW
FRIDAY, NOVEMBER 3, 2006
8.50 – AM 1.30 – PM
SESSION 1
THE PIONEERS & THE BEGINNING
Chairs: donald price carl cotman
john growdon
charles duyckaerts
SATURDAY, NOVEMBER 4, 2006
9 – AM 1 – PM
Chairs:
SESSION 2
CURRENT CONCEPTS
rudy tanzi
david holtzman
Chairs:
SESSION 3
CHALLENGES FOR THE
FUTURE
karen duff
john hardy

8.50 am Welcome: Mathias Jucker
Yves Christen
9 - 9.30 am
Robert Terry
(University of California, La Jolla, USA)
Mid twentieth century Alzheimer considerations.
covering the work of:
P. Divry
Divry P (1927) Etude histo-chimique des plaques seniles. J Belge Neurol Psychiat 27: 643-57.
J. A. N. Corsellis
Corsellis JAN, Brierley JB (1954) An unusual type of pre-senile dementia (atypical Alzheimer’s disease with amyloid
vascular change). Brain 77: 571-87.
G. Margolis
Margolis G (1959) Senile cerebral disease: a critical survey of traditional concepts based upon observations with
newer techniques. Lab Invest 8: 335-70 .
H. Sjogren
Sjogren H, Sourander P (1961) Clinical, histological and chemical studies on pre-senile and senile neuropsychiatric
diseases. Proc Collegium Internat Neuro-psychopharm Colloquium 555-64.
M. Kidd
Kidd M (1963) Paired helical filaments in electron microscopy of Alzheimer’s disease. Nature 197: 192-3
R. D. Terry
Terry RD, Gonatas NK, Weiss M (1964) Ultrastructural studies in Alzheimer's presenile dementia. Amer J Pathol 44:269-297.
N.K. Gonatas
Gonatas NK, Anderson A, Evangelista I (1967) The contribution of altered Synapses in the senile plaque:
an electron microscopic study in Alzheimer’s dementia. J Neuropath Exp Neurol 26: 25-39.
H. M. Wisniewski
Wisniewski HM, Shelanski ML, Terry RD (1968) Effects of mitotic spindle inhibitors on neurotubules and neurofilaments
in anterior horn cells. J Cell Biol 38: 224-9.
B. E. Tomlinson, G. Blessed, M. Roth
Tomlinson BE, Blessed G, Roth M (1968) The association between quantitative measures of dementia and of senile
changes of the cerebral gray matter of elderly subjects. Brit J Psychiat 114: 797-811.
D. A. Drachman
Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. Arch Neurol 30: 113-21.
R. Katzman
Katzman R (1976) the prevalence and malignancy of Alzheimer’s disease; a major killer. Editorial in Arch Neurol 33: 217-8

9.30 – 10.45 am
Khalid Iqbal
(Institute of Basic Research in Developmental Disabilities, Staten Island, USA)
Bulk isolation of tangles and abnormal hyperphosphorylation of tau.
Iqbal K, Wisniewski HM, Shelanski ML, Brostoff S, Liwnicz BL, Terry RD (1974) Protein changes in senile dementia.
Brain Research 77: 337-43
Peter Davies
(Albert Einstein College of Medicine, Bronx, USA)
The cholinergic deficiency in Alzheimer’s disease.
Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2: 1403
Cai’ne Wong
(Scarborough, Maine, USA)
Purification and characterisation of ß-amyloid.
Glenner CG, Wong CW (1984)Alzheimer’s Disease: Initial Report of the Purification and Characterization
of a Novel Cerebrovascular Amyloid. Protein Biochem & Biophy Research Communications 120: 885-90
Colin Masters
(University of Melbourne, Parkville, Australia)
The neuronal and proteolytic origin of Aß-amyloid in Alzheimer’s disease.
Masters CL, Simms G, Weinman NA, McDonald BL, Multhaup G, Beyreuther K (1985) Amyloid plaque core protein in
Alzheimer disease and Down syndrome. Proc Nat Acad Sci USA 82: 4245-9
Jean-Pierre Brion
(Free University of Brussels Medical School, Brussels, Belgium)
Immunological demonstration of tau protein in neurofibrillary tangles.
Brion JP, Passareiro H, Nunez J, Flament-Durand J (1985) Mise en évidence immunologique de la protéine tau au
niveau des lésions de dégénérescence neurofibrillaire de la maladie d’Alzheimer (Immunological demonstration
of tau protein in neurofibrillary lesions of Alzheimer’s disease). Archives de Biologie (Bruxelles) 95: 229-35.
10.45 – 11.15 am Coffee Break

11.15 – 12.30 am
Konrad Beyreuther
(University of Heidelberg, Heidelberg, Germany)
Discovery of the APP gene.
Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K & Muller-Hill B (1987)
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-6
Rudolph E. Tanzi
(Massachusetts General Hospital, Charlestown, USA)
APP: from gene discovery to therapeutic strategies.
Tanzi RE, Gusella JF, Watkins PC, Bruns GAP, St George-Hyslop PH, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL (1987)
The amyloid beta protein gene: cDNA cloning, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235: 880-4
Yasuo Ihara
(University of Tokyo, Tokyo, Japan)
Ubiquitin is a component of paired helical filaments in Alzheimer's disease.
Mori H, Kondo J, Ihara Y (1987) Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235: 1641-4
Michel Goedert
(MRC Laboratory of Molecular Biology, Cambridge, UK)
Tau protein is an integral component of the paired helical filament.
Goedert M, Wischik CM, Crowther RA, Walker JE and Klug A (1988) Cloning and sequencing of the cDNA encoding a
core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau.
Proc Natl Acad Sci 85: 4051-5
Mony de Leon
(New York University School of Medicine, New York, USA)
Hippocampal imaging in the early diagnosis of AD.
de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC (1989) Early marker for
Alzheimer's disease: The atrophic hippocampus. Lancet 2: 672-3.
12.30 – 1.30 pm Lunch

1.30 – 3.15 pm
Sangram S. Sisodia
(University of Chicago, Chicago, USA)
Proteolytic processing of APP in vitro and in vivo.
Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL (1990) Evidence that b-amyloid protein in
Alzheimer’s disease is not derived by normal processing. Science 248: 492-5
Bruce Yankner
(Children’s Hospital, Boston, USA)
The neurotoxicity of amyloid-ß protein.
Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of
amyloid beta protein: reversal by tachykinin neuropeptides. Science 250: 279-82
Blas Frangione
(New York University School of Medicine, New York, USA)
APP mutation causes hemorrhagic stroke with cerebral amyloid angiopathy.
Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, Frangione B (1990)
Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type. Science 248: 1124-6.
Peter St George-Hyslop
(University of Toronto, Toronto, Canada)
Genetic linkage studies suggest that AD is not a single homogeneous disorder
St George-Hyslop PH et al (1990) Genetic linkage studies suggest that Alzheimer’s disease is not a single homogeneous disorder. Nature 347: 194-7
Heiko Braak
(Goethe University, Frankfurt, Germany)
Neuropathological stageing of Alzheimer related changes.
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer related changes. Acta Neuropathol 82: 239-59
Alison Goate
(Washington University School of Medicine, Saint Louis, USA)
Missense mutations in the ßAPP gene cause of early onset familial AD.
Goate AM et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial AD. Nature 349: 704-6
Gerard D. Schellenberg
(University of Washington, Seattle, USA)
Genetic linkage evidence for a familial AD locus on chromosome 14.
Schellenberg GD et al (1992) Genetic linkage evidence for a familial Alzheimer Disease locus on chromosome 14. Science 258: 668-71
3.15 – 3.45 pm Coffee Break

3.45 – 5.20 pm
Christian Haass
(Ludwig Maximilians University, Munich, Germany)
Physiological generation of Amyloid ß-peptide by ß- and !-secretases.
Haass C et al (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359: 322-5
Allen Roses (by video)
(Glaxo SmithKline, Research Triangle Park, USA)
Gene dose of apolipoprotein E type 4 allele and the risk of AD.
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E high-avidity binding
to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90:1977-81.
Steven Younkin
(Mayo Clinic Jacksonville, Jacksonville, USA)
Elevated Aß42 by early onset familial Alzheimer's disease mutations.
Scheuner D et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased
in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-70
Karen Ashe
(University of Minnesota Medical School, Minneapolis, USA)
A transgenic mouse model with amyloid plaques.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996)
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102
Mike Hutton
(Mayo Clinic Jacksonville, Jacksonville, USA)
The genetics of FTDP-17 and PSP.
Hutton, M et al (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393: 702-5
Martin Citron
(Amgen Inc., Thousand Oaks, USA)
Cloning of ß-secretase.
Vassar R et al (1999) ß-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
Science 286: 735-41
Dale Schenk
(Elan Pharmaceuticals, South San Francisco, USA)
Aß immunotherapy prevents Alzheimer's disease neuropathology.
Schenk D et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-7

9.00
9.15
9.30
9.45
10.00
Christine Van Broeckhoven
(University of Antwerpen, Antwerpen, Belgium)
Current concepts in AD genetics.
Bradley Hyman
(Massachusetts General Hospital, Boston, USA)
Molecular neuroanatomy of Alzheimer’s disease.
Takaomi Saido
(RIKEN Brain Science Institute, Saitama, Japan)
Metabolism of amyloid-ß peptide.
Bart De Strooper
(Center for Human Genetics, Leuven, Belgium)
Heterogeneity and complexity
of the !-secretase/presenilin protease.
Michael S. Wolfe
(Brigham and Women’s Hospital, Boston, USA)
Targeting !-secretase.
10.15 – 10.45 am Coffee Break

10.45
11.00
11.15
11.30
11.45
Eckhard Mandelkow
(Max-Planck Institute, Hamburg, Germany)
Tau protein in neurodegeneration.
Virginia Lee
(University of Pennsylvania, Philadelphia, USA)
Brain amyloidosis linked to tau and
alpha-synuclein interactions.
William E. Klunk
(University of Pittsburgh School of Medicine, Pittsburgh, USA)
Imaging the pathology of Alzheimer’s disease patients.
John C. Morris
(Washington University School of Medicine, Saint Louis, USA)
Detecting early-stage and preclinical Alzheimer's disease.
Roger M. Nitsch
(University of Zurich, Zurich, Switzerland)
Aß-immunization in Alzheimer’s disease.
12 – 1 pm Lunch

1.00
1.15
1.30
1.45
2.00
2.15
Monique M.B. Breteler
(Erasmus University Medical Center, Rotterdam, Netherlands)
Towards the prevention of Alzheimer’s disease.
Nick Fox
(National Hospital for Neurology & Neurosurgery, London, UK)
Seeing what Alzheimer couldn’t see:
imaging the onset and progression of atrophy.
Todd E. Golde
(Mayo Clinic Jacksonville, Jacksonville, USA)
Magic bullets or magic shotguns to treat or prevent AD?
John Hardy
(National Institute on Aging, Bethesda, USA)
What if the amyloid deposition process has a physiological function?
Takeshi Iwatsubo
(University of Tokyo, Tokyo, Japan)
Challenges for the enigma of Aß and !-secretase.
Zaven Khachaturian
(Khachaturian, Radebaugh & Associates Inc., Potomac, USA)
Prospects of preventing Alzheimer’s in the 21 st century:
challenges, barriers & opportunities.
2.30 – 3 pm Coffee Break

3.00
3.15
3.30
3.45
4.00
4.15
Steven Paul
(Eli Lilly Research Laboratories, Indianapolis, USA)
Therapeutic opportunities:
testing the amyloid cascade hypothesis.
Donald L. Price
(Johns Hopkins University School of Medicine, Baltimore, USA)
Models and experimental therapeutics:
a vision for the future.
Dennis Selkoe
(Brigham and Women’s Hospital, Boston, USA)
The seventh age of man: solving senility.
Leon Thal
(University of California San Diego School of Medicine, La Jolla, USA)
How do we test drugs in AD?
John Trojanowski
(University of Pennsylvania, Philadelphia, USA)
Tau focused drug discovery for AD.
Bengt Winblad
(Karolinska Institute, Huddinge, Sweden)
Can we afford good quality of care of AD patients,
or... "precipice"?

CLINIC FOR PSYCHIATRY, UNIVERSITY OF TÜBINGEN
The symposium will take place at this
historic building, the Klinik für
Gemüts- und Nervenheilkunde,
where the “37. Versammmlung
Südwestdeutscher Irrenärzte“
gathered on November 3 and 4,
1906. At this meeting Alois Alzheimer
presented his seminal Alzheimer’s
disease case to his colleagues;
among them were Franz Nissl, Robert
Gaupp, Oswald Bumke, Hans
Curschmann, Otto Binswanger, and C.G. Jung, all of whom now have important places
in the history of medicine. Prof. Gerhard Buchkremer has been the clinic’s director since
1990.
EXHIBITION ON THE HISTORY OF MICROSCOPY
In collaboration with Carl Zeiss GmbH we
have put up a small exhibition on the
History of Microscopy in Alzheimer
Research at the Clinic of Psychiatry in the
library, on the 1st floor. The exhibition will
be open to the public on Thursday
afternoon, and to symposium attendees
from Thursday afternoon until Saturday
afternoon.
We would like to thank Heiko Braak, Mony de Leon, Virginia García Marin, Michel
Goedert, Bill Klunk, Colin Masters, George Perry, Robert Terry, and Dennis Selkoe for
sending us their images.

CITY TOURS
On Thursday, Nov 2, you have
the opportunity to join city tours
through the beautiful old city of
Tübingen, which are sponsored
by the mayor.
Emphasis will be on famous
German poets and thinkers as
well as on the history of
science, e. g. on the work of
Friedrich Miescher, who
discovered the DNA in his
laboratory at the local castle,
the famous Hölderlin tower,
and following Alois Alzheimer’s
tracks.
For further information on the
city of Tübingen please see the
city’s homepage:
www.
tuebingen.de/en/1559.html.
The first German tour will start at 1 pm from the Marktplatz and end at the Clinic for
Psychiatry, the symposium’s venue, where the second tour will start at 3 pm.
The English tour will start at 3.30 pm at the Clinic for Psychiatry, and will end at about
5.30 pm at the Neue Aula, where the Public Session will take place.

THEATER
The play „Die Akte Auguste D.“
about the life and work of Alois
Alzheimer, written by Konrad and
Ulrike Maurer, has been sucessfully
staged in Zürich and Frankfurt. The
play will now be staged under the
direction of Simone Sterr, the new
theater director of Tübingen.
Although the play will be put on
stage in German, it can be equally
understood by English speakers as
translation will be provided by
earphones. Attendees will be able
to enjoy the play in a historic
lecture hall at the Institute of
Anatomy (Fri, 9 pm)
CONFERENCE DINNER
The conference dinner will be held at
the Museum Restaurant, the same
location where the participants of the
gathering had dinner 100 years ago.
(Sat, 8 pm)

ALZHEIMER’S BIRTHPLACE
On Sunday, November 5, participants will have the opportunity to visit Alois Alzheimer’s
birthplace. The 19th century house has been carefully restored and exhibits little
treasures such as a microscope Alzheimer worked with and the original medical record
and brain sections of Auguste D. This historical
site gives you the rare opportunity to gain
valuable insight into Alzheimer’s life and
research accomplishments. It is located in
Marktbreit, a charming old town approx. 150
km southeast of Frankfurt and is a short side trip
en route from Frankfurt to Tübingen.
Alzheimer’s biographers, Konrad und Ulrike
Maurer, will be your guides for the entire day,
give you a tour through the town and
birthplace, and will do their best to answer all
your questions regarding Alois Alzheimer’s life
and work.
For a detailed description of the birthplace
please see pages 141–157 in: “Alois Alzheimer –
His Life and Work with Text and Photographs”
which you will find in your conference bag.
Itinerary:
9.00 Bus departure from Tübingen (Hotel Domizil) to Markbreit
11.15 – 13.45 Guided tours of Alzheimer’s House, Ochsenfurter Straße 15, Marktbreit.
Lunch at Hotel Löwen
13.45 Bus departure from Marktbreit to Tübingen via Würzburg train station
from where you have a direct train connection to Frankfurt airport.
For further information please address Konrad Maurer at the conference.
Please make sure to bring along about ! 40 in cash for the bus ride and for lunch.

LOCATION
Symposium:
University Clinic for Psychiatry
Osianderstraße 25
D - 72076 Tübingen
Germany
Public Session:
Neue Aula, University of Tübingen
Wilhelmstraße 7
D - 72076 Tübingen
Germany
LANGUAGE
English is the official language of the symposium. The public session and the theater
performance on Thursday, Nov 2, will be held in German.
CLIMATE
The average November temperature in Tübingen is between 3 – 14 °C. We hope we will
enjoy some beautiful fall days but advisably you should also be prepared for some rain.

AIRPORT INFORMATION
Most airplanes from overseas arrive in
Frankfurt, which is located approximately
250 km north of Tübingen. The trainride from
Frankfurt to Tübingen via Stuttgart takes 2 –
2 ! hours, during the day trains run every
30-60 minutes.
Stuttgart airport is located approximately 50
km north of Tübingen, which you can then
reach by taxi or bus. The taxi fare will cost
approximately " 50. Depending on the
means of transport the journey will take 30-
60 minutes.
REGISTRATION
Due to space limitations in the historical lecture hall the number of participants is
limited to 181 people. There is no registration fee for the meeting but a fee will be
charged for the Conference Dinner. All attendees (except speakers and SAB members)
who would like to join are asked to pay " 50 cash on registration.
Registration will be open at the Clinic for Psychiatry on Thursday from 2 until 5 pm and
on Friday from 8 am until 5.30 pm.
LIVE VIDEO STREAM & DVD
The entire conference can be watched as a live video stream via the Internet during
and after the meeting, and a DVD will be available after the meeting. For further
information please see www.alz100.de/live_video.html.

LIST OF SPONSORS
Abbott
Boehringer Ingelheim
Eisai Europe & Pfizer Inc
Elan Pharmaceuticals
Hoffmann-La Roche
Novartis
Thank you
also to Astrid de Gérard from Ipsen, Brigitte Russ-Scherer, the mayor of Tübingen, all the helpful hands from the
university, and the many, many great helpers from the Hertie Institute, in particular to Daniel Eicke, Christian
Ehrhardt, Friedemann Bunjes, Janaky Coomaraswamy, Chris Feichtinger, and Bernadette Graus.

LOCAL ORGANIZATION
Hertie Institute for Clinical Brain Research
Department of Cellular Neurology
Prof. Dr. Mathias Jucker
Otfried-Müller-Str. 27
D - 72076 Tübingen, Germany
Administrative Secretariat
Simone Eberle
Phone: +49-7071-29 81947
Fax: +49-7071-29-4521
e-mail: info@alz100.de
www.hih-tuebingen.de/en/
www.alz100.de
Please address suggestions, comments, and questions to the organizers at
info@alz100.de.
For further information please see www.alz100.de